Fig. 5From: Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillanceSDQ score. Total difficulties score: 21.1 ± 5.5 at baseline, 18.0 ± 5.5 at Week 24, 17.0 ± 6.0 at Week 52, 17.3 ± 5.8 at end-point (LOCF). Prosocial behavior subscale: 3.5 ± 2.5 at baseline, 4.2 ± 2.6 at Week 24, 4.3 ± 2.5 at Week 52, 4.3 ± 2.7 at end-point (LOCF)Back to article page